Abstract
The aim of this study was to investigate the presence of movement disorders associated with ifosfamide toxicity. One of the most common adverse events of ifosfamide treatment is central nervous system toxicity. However, little is known about the occurrence of movement disorders associated with ifosfamide toxicity. We performed a retrospective computer search of the electronic medical records database of the Mayo Clinic, Rochester, MN from 1 January 1997–30 June 2010, using a series of search terms to identify all patients that had been treated with ifosfamide for systemic cancer. Among 400 patients that have ever used ifosfamide, we selected those patients that had any neurological complication in their medical records after the use of ifosfamide. Fifty-two had a neurological complication after ifosfamide administration. The most common neurological complication was encephalopathy that was present in 11 cases (21%). The presence of a movement disorder time locked to the administration of ifosfamide was reported in seven cases (13%). Generalized myoclonus was most common, occurring in four patients while postural tremor was documented in the other three. All patients with myoclonus had asterixis. Four of the patients also had encephalopathy. In six patients the movement disorders resolved within 48 h, spontaneously, after the discontinuation of ifosfamide, while in one case resolved in 24 h after the treatment with methylene blue. Our study demonstrates that although encephalopathy is the most common adverse neurological event associated with ifosfamide toxicity, movement disorders, including generalized myoclonus, asterixis, and postural tremors may also occur. Treatment with methylene blue may be further considered as useful to ameliorate the movement disorders.
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Klastersky J (2003) Side effects of ifosfamide. Oncology 65(Suppl 2):7–10
Brunello A, Basso U, Rossi E, Stefani M, Ghiotto C, Marino D et al (2007) Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature. Drugs Aging 24(11):967–973
Ajithkumar T, Parkinson C, Shamshad F, Murray P (2007) Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol) 19(2):108–114
Ames B, Lewis LD, Chaffee S, Kim J, Morse R (2010) Ifosfamide-induced encephalopathy and movement disorder. Pediatr Blood Cancer 54(4):624–626
Brefel-Courbon C, Gardette V, Ory F, Montastruc JL (2006) Drug-induced myoclonus: a French pharmacovigilance database study. Neurophysiol Clin 36(5–6):333–336
Fahn S (2010) Involuntary Movements, 12th edn. Williams and Wilkins, Lippincott
Patel PN (2006) Methylene blue for management of Ifosfamide-induced encephalopathy. Ann Pharmacother 40(2):299–303
Kupfer A, Aeschlimann C, Cerny T (1996) Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 50(4):249–252
Conflict of interest
The authors report no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Savica, R., Rabinstein, A.A. & Josephs, K.A. Ifosfamide associated myoclonus-encephalopathy syndrome. J Neurol 258, 1729–1731 (2011). https://doi.org/10.1007/s00415-011-5990-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-011-5990-4